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Abstract
Background: Toxic liver diseases are mainly caused by drug-induced liver injury (DILI). We assessed incidences and
outcomes of DILI including associated factors for mortality.
Methods: We performed a population-based study of hospitalized patients with DILI. Information was retrieved
from the Nationwide Hospital Admission Data using ICD-10 code of toxic liver diseases (K71) and additional codes
(T36–T65). The associated factors were analyzed with log-rank test, univariate and multiple cox regression analysis.
Results: During 2009–2013, a total of 159,061 (average 21,165 per year) admissions were related to liver diseases.
6,516 admissions (1,303 per year) were due to toxic liver diseases. The most common type of toxic liver disease
was acute hepatitis (33.5 %). In-hospital and 90-day mortality rates were 3.4 % and 17.2 %. DILI with cirrhosis
yielded the highest in-hospital and 90-day mortality rates (15.8 % and 47.4 %). Acetaminophen, cirrhosis and age ≥
60 years were seen in 0.5 %, 8.3 % and 50.1 % of patients who died versus 5 %, 2.3 % and 32.4 % of survivors.
Factors associated with mortality were cirrhosis (HR 2.72, 95 % CI: 2.33–3.19), age ≥60 years (HR 2.16, 95 % CI:
1.96–2.38), human immunodeficiency viral infection (HR 2.11, 95 % CI: 1.88–2.36), chronic kidney disease (HR 1.59, 95 %
CI: 1.33–1.90), chronic obstructive pulmonary disease and bronchiectasis (HR 1.55, 95 % CI: 1.17–2.04), malnutrition
(HR 1.43, 95 % CI: 1.10–1.86) and male (HR 1.31, 95 % CI: 1.21–1.43). Acetaminophen DILI yielded lower risks of mortality
(HR 0.24, 95 % CI: 0.13–0.42). The most common causes of DILI were acetaminophen (35.0 %) and anti-tuberculous
drugs (34.7 %).
Conclusions: DILI is an uncommon indication for hospitalization carrying lower risks of death except in patients with
non-acetaminophen, cirrhosis, elderly or concomitant diseases.
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Background
Liver injury which is caused by drugs and herbal supple-
ment is an infrequent but increasing health problem.
About 52 % of reported cases of acute liver failure (ALF)
in the United States were related to drug-induced liver in-
jury (DILI) [1]. The incidence of DILI in medical inpa-
tients was estimated to be approximately 1 in 100 patients
[2, 3]. However, the prevalence of DILI in Asia has not
been well described [4]. From the Drug-Induced Liver In-
jury Network (DILIN) studies, 15.5 % of patients with liver
injury were caused by herbal and dietary supplements [5].
In Asian countries, there have been conflicting reports of
the number of herbal DILI [6, 7]. However, a subsequent
systematic review in reported the incidence of DILI of
0.71 % after exposure to herbal remedies [7].
The International Classification of Disease (ICD) revi-
sion 10 system has been used in Thailand’s administra-
tive and health care database for the identification of
patient cohorts and financial works [8]. The ICD-10
code for toxic liver disease, or K71 (ICD-10 codes are
shown in italics all through this paper), is aimed to de-
fine drug-induced idiosyncratic (unpredictable) liver dis-
ease and drug-induced toxic (predictable) liver disease.
Additional external cause codes (T36–T65) are often re-
quired after the coding of toxic liver diseases in order to
identify the cause of DILI [9, 10]. Toxic liver diseases are
mainly contributed by DILI [7]. Since 2002, the Univer-
sal Coverage Scheme has been implemented in Thailand
for people whose health care cost is neither covered by
the Social Health Insurance Scheme nor the Civil
Servant Medical Benefit Scheme [11]. Currently, the
Universal Coverage Scheme covers the health care cost
of more than 47 million people (75 % of Thai popula-
tion) [11]. To address the less well-described DILI in this
region, we assessed incidences, presentation, outcomes
and economic burden of hospitalized patients with DILI
including the risk factors of mortality in Thai population
from the large database of the Nationwide Hospital
Admission Data.
Methods
Data source and study population
The study protocol was approved by the Committee on
Human Rights related to Research Involving Human
Subjects, Faculty of Medicine, Ramathibodi Hospital (ID
07–59–60) and it was carried out according to the Good
Clinical Practice Guideline without obtaining inform
consent. We performed a population-based study of hos-
pitalized adult patients aged at least 19 years old with
DILI whose health care cost was under the Universal
Coverage Scheme in all 77 provinces to evaluate the
incidences and outcomes of DILI including associated
factors for mortality in Thailand. All data were retro-
spectively retrieved from the 2009 to 2013 Nationwide
Hospital Admission Data from the National Health Se-
curity Office (NHSO), Thailand, which included more
than 75 % of Thai population, by using the International
Classification of Diseases, 10th edition (ICD-10) code in-
dicative of toxic liver diseases (K71). Individual patients
with one of the ICD-10 codes entered between January
1, 2009 and December 31, 2013 were identified. The
diagnosis of DILI in the NHSO database was performed
by physicians in their clinical practice without obligation
to use specific and objective diagnostic criteria such as
the Roussel Uclaf Causality Assessment Method
(RUCAM) or its previous term, the Council for Inter-
national Organization of Medical Sciences (CIOMS)
[12], which can be the study limitation. However, the
bias in the diagnosis of DILI was controlled by further
examining additional external cause codes of ICD-10,
chiefly the poisoning by drugs and biologic substances
(T36–T50) and the toxic effects of substances from non-
medicinal sources (T51–T65). In Thailand, hospitals are
classified into three levels, i.e. primary, secondary and
tertiary hospitals. The baseline characteristics, demo-
graphic data, length of hospital stay, admission cost, out-
comes and causes of DILI were collected and analyzed.
Availability of data and materials
All available raw data will not be shared as it consisted
of confidential patient information that abide by the
signed contract and regulation. All other relevant study
data are presented in the tables.
Statistical analysis
Continuous variables were compared among groups
using one-way ANOVA and Kruskal Wallis tests as ap-
propriate. Categorical variables were compared among
groups using χ2 and Fisher’s exact test. Factors associ-
ated with mortality were analyzed with log-rank test,
univariate and multiple cox regression analysis. The haz-
ard ratio [HR] and 95 % confidence interval (CI) of each
factor has been demonstrated. A P <0.05 was considered
statistically significant. Statistical analysis was performed
with SPSS version 13 (SPSS Inc., Chicago IL).
Results
Demographic and admission data of hospitalized patients
with DILI
During 2009–2013, a mean of 5.6 million admissions
from all causes occurred per year. A total of 159,061 ad-
missions (or 21,165 admissions per year) were related to
liver diseases. 6,516 admissions (or 1,303 admissions per
year) were due to DILI (Table 1). The average annual ad-
mission rates of DILI were 4.1 % of all liver disease ad-
missions and 0.12 % of the total admissions. The
incidence rates of DILI did not significantly change over
the study period (0.11 %, 0.11 %, 0.12 %, 0.12 %, 0.13 %,
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P = 0.058). The mean age of the study patients was 51.9
± 18.6 years. The mean length of hospital stay was 6.7 ±
6.7 days. The average health care cost of admission of
DILI was 533,955 ± 53,532 USD per year, which was
about 5.4 % and 0.1 % of the health care cost of admis-
sion due to liver diseases (9,888,056 USD) and overall
gastrointestinal diseases (391,512,096 USD).
From the available recorded data (of 589 cases), the
two most common causes of DILI were 4-aminophenol
(T39.1) which is the primary degradation product of
acetaminophen [13], and anti-mycobacterial drugs
(T37.1, T36.6) (35 % and 34.6 %, respectively) (Table 2).
The risks of in-hospital and 90 day mortality
The average in-hospital and 90-day mortality rates of
DILI were 3.4 % and 17.2 %, which were lower than
those of overall liver diseases (6.8 % and 29.2 %) (P <
0.001). The highest number of DILI was found in the
northeastern region and primary health care centers
(Tables 3 and 4). However, the greatest in-hospital mor-
tality rates were seen in Bangkok and in patients who
were admitted in tertiary health care centers despite the
lowest number of case admission in these sectors.
The distribution of DILI types
The three most common types of DILI were acute hepa-
titis (K71.2) (33.5 %), not elsewhere classified hepatitis
(K71.6) (27.3 %) and hepatic necrosis (K71.1) (25.6 %)
(Table 5). DILI that occurred on top of cirrhosis (K71.7)
notably yielded the highest in-hospital and 90-day mor-
tality rates (15.8 % and 47.4 %). DILI with chronic lobu-
lar hepatitis (K71.4) and cholestasis (K71.0) were the
second and third patterns of DILI associated with the
in-hospital mortality. Chronic active hepatitis (K71.5)
and chronic lobular hepatitis (K71.4) were ranked the
second and third types of DILI related to the 90-day
mortality.
Independent factors associate with mortality in patients
having DILI
Acetaminophen, cirrhosis and age ≥ 60 years were seen
in 0.5 %, 8.3 % and 50.1 % of patients who died,
Table 2 The list of common drugs and substances as the
causes of drug-induced liver injury (DILI) in 589 cases
Drug or substance Number %
Acetaminophen (T39.1) 206 35
Antimycobacterial drugs (T37.1 and T36.6) 204 34.6
Other and unspecified drugs and substances (T50.9) 34 5.8
Antiviral drugs (T37.5) 22 3.7
Ingested mushroom (T62.0) 16 2.7
Herbicides and fungicides (T60.3) 13 2.2
Antihyperlipdemia and antiarteriosclerotic drugs (T46.6) 7 1.2
Aminoglycosides (T36.5) 6 1.0
Other antibiotics (T36.8) 6 1.0
Other nonsteroidal anti-inflammatory drugs (T39.3) 6 1.0




Table 3 The number (%) of patients with drug-induced liver injury
(DILI) and in-hospital mortality according to country regions





Central 703 11.4 36 5.1
Northeast 2421 39.2 34 1.4
North 588 9.5 24 4.1
South 650 10.5 15 2.3
Other 1311 21.2 56 4.3
Bangkok 501 8.1 31 6.2
Totala 6174 100.0 196 3.2
amissing data in 2 patients
Table 1 Annual incidence and demographic data of patients who were admitted with drug-induced liver injury (DILI) from 2009 to
2013 in Thailand
2009 2010 2011 2012 2013 Average
Annual admissions, n 1,197 1,244 1,312 1,362 1,401 1,303
% of admissions (per liver diseases) 4.2 4.1 4.1 4.1 4.0 4.1
% of admissions (per total admissions) 0.11 0.11 0.12 0.12 0.13 0.12
Male, n (%) 603 (50) 634 (51) 677 (52) 720 (53) 724 (52) 671.6 (51.5)
Age, years 52.4 ± 18.5 52.2 ± 18.6 50.4 ± 18.5 52.7 ± 18.6 52.3 ± 18.8 52.0 ± 18.6
Length of hospital stay, days 6.9 6.8 6.9 6.5 6.4 6.7 ± 6.7
Cost of hospitalization, USD 443,230 535,600 545,650 565,661 579,636 533,955 ± 53,532
Mortality, n (%)
In-hospital mortality 34 (2.8) 44 (3.5) 52 (4.0) 47 (3.5) 42 (3.0) 43.8 (3.4)
90 day mortality 288 (24.0) 251 (20.0) 233 (18.0) 202 (15.0) 144 (10.0) 223.6 (17.2)
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comparing to 5 %, 2.3 % and 32.4 % of those who sur-
vived. Table 6 shows that the independent factors associ-
ate with mortality in DILI were acetaminophen (hazard
ratio [HR] 0.24, 95 % confidence interval [CI]:0.13–0.42),
cirrhosis (HR 2.72, 95 % CI: 2.33–3.19), age ≥60 years
(HR 2.16, 95 % CI: 1.96–2.38), human immunedeficiency
virus (HIV) (HR 2.11, 95 % CI: 1.88–2.36), chronic kid-
ney disease (CKD) (HR 1.59, 95 % CI: 1.33–1.90),
chronic obstructive pulmonary disease (COPD)/bronchi-
ectasis (HR 1.55, 95 % CI: 1.17–2.04), malnutrition (HR
1.43, 95 % CI: 1.10–1.86), and being male (HR 1.31, 95
% CI: 1.21–1.43). The etiology of non-acetaminophen,
cirrhosis and elderly (age ≥60) yielded significant impact
on long-term survival (P < 0.001) (Fig. 1).
Discussion
From the Nationwide Hospital Admission Data of
Thailand, about 1.2 of 100 admissions were due to DILI,
which is close to the report from previous studies [2, 3].
The pattern of acute hepatitis or hepatocellular injury
was the most common presentation of DILI in this study
and others [2, 4, 14]. The outcome of cholestatic DILI
was reportedly to be better than hepatocellular DILI.[2]
Although, the cost of admission due to DILI was about
5.4 % of liver diseases and 0.1 % of overall gastrointes-
tinal diseases, the in-hospital and 90-day mortality rates
of DILI were about 3.4 % and 17.2 %. The highest in-
hospital and 90-day mortality rates that were noticed in
Bangkok and in tertiary care centers are explained by
the policy of referral system of Thailand. From previous
studies, jaundice, female sex, and hepatocellular injury
were found to associate with the development of ALF,
death and the need for liver transplantation [2, 15]. DILI
patients who had liver cirrhosis, even without jaundice,
had the highest risk of mortality in this study. The find-
ing supports the significant impact of having pre-
existing liver diseases on increasing severity of DILI and
risks of mortality [16]. In addition, individual ages 60 or
over and those with medical comorbidities were more
likely to have higher mortality. These finding are in con-
trast to a conclusion from a previous study which
showed that individuals 65 years or older did not have
higher mortality as they were more likely to have chole-
static liver injury [16]. A lower risk of mortality in pa-
tients with acetaminophen-related DILI was revealed in
this study. From a previous study, the mortality rate of
Table 4 The number (%) of patients with drug-induced liver injury
(DILI) and in-hospital mortality according to hospital levels





Primary level 2575 41.7 33 1.3
Secondary level 1960 31.7 84 4.3
Tertiary level 1639 26.5 79 4.8
Totala 6174 100.0 196 3.2
amissing data in 2 patients
Table 5 The number (%) of patients and mortality rates
classified according to the types of drug-induced liver
injury (DILI)




Cholestasis (K71.0) 329 5.3 6.1 24.0
Hepatic necrosis (K71.1) 1580 25.6 4.2 21.7
Acute hepatitis (K71.2) 2072 33.5 2.2 17.3
Chronic persistent
hepatitis (K71.3)
29 0.5 3.5 24.1
Chronic lobular hepatitis
(K71.4)
13 0.2 7.7 30.8
Chronic active hepatitis
(K71.5)
7 0.1 0.0 42.9
Hepatitis, not elsewhere
classified (K71.6)
1685 27.3 2.7 19.5
Fibrosis and cirrhosis of
liver (K71.7)
57 0.9 15.8 47.4
Other disorders of liver
(K71.8)
46 0.7 2.2 30.4
Unspecified (K71.9) 358 5.8 1.4 18.2
Total 6176 100.0 3.2 19.9
Table 6 Independent factors associate with mortality in drug-
induced liver injury (DILI)
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acetaminophen-induced ALF was lower than non-
acetaminophen-induced ALF (5.6 % vs. 21.4 %) [1]. A
large retrospective cohort study in the United States
demonstrated that acetaminophen, dietary/herbal sup-
plements and antimicrobials were the common causes
of drug-induced ALF in 56.3 %, 18.8 % and 6.3 %, re-
spectively [1].
Many reports following prospective studies in the
United States and Spain showed that antimicrobial
agents especially amoxicillin-clavulanate were the most
common drugs relating to DILI [2, 16, 17]. Based on the
available data of 589 cases, the leading causes of DILI
were acetaminophen and anti-tuberculous drugs. The
common causes of DILI that were reported from Asian
countries were anti-tuberculous drugs, antibiotics and
anticonvulsants [4, 15]. Herbal remedies, or complemen-
tary and alternative medicines, have frequently been a
common factor of DILI in this part of the world [4, 6,
14]. Herbal remedies were not found to be an important
cause of DILI in Thai population due to a low number
of herbal remedies recorded under the code F55.1.
Nevertheless, we cannot conclude that herbal remedies
do not contribute to DILI in Thailand.
As a retrospective study with nationwide database, our
report has some limitation in term of data missing and
the diagnostic criteria of DILI. The accuracy of data
Fig. 1 Cumulative survival of patients with drug-induced liver injury (DILI) in relation to acetaminophen or non-acetaminophen drugs as the
cause of DILI, cirrhotic status and age. a Acetaminophen vs. non-acetaminophen. b Cirrhosis vs. non-cirrhosis. c Age≥ 60 or < 60 years
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depends upon data input by health care workers. Using
the ICD-10 code to identify DILI and adverse drug
events may be subjected to substantial variability includ-
ing false positive and false negative results [8, 9].
RUCAM, a well-established, structured and standardized
tool to assess causality and diagnose in cases of sus-
pected DILI and HILI [12], was not employed in this
study. A further prospective study using RUCAM is
needed to systematically investigate all aspects of DILI
in Thailand.
Conclusions
DILI is an uncommon clinical indication of
hospitalization, but it carries higher risk of death in
cirrhotic patients, elderly, male gender or having
medical comorbidities. Our study provides a basis
for future research in the field of DILI.
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